Login to Your Account



Gilead's Truvada Gets ADAC Thumbs Up in HIV Prevention

By Jennifer Boggs
Managing Editor

Friday, May 11, 2012
After an all-day meeting that stretched into the evening, the FDA's Antiviral Drugs Advisory Committee (ADAC) voted to recommend approval of Gilead Sciences Inc.'s HIV drug Truvada to prevent infection in adults at high risk of contracting the disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription